{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:52:16Z","timestamp":1787496736130,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jacasi.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:41:38Z","timestamp":1696948898000},"page":"908-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk\u00a0of HF and AF"],"prefix":"10.1016","volume":"3","author":[{"given":"Ryusei","family":"Ohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Fujiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-114X","authenticated-orcid":false,"given":"Nobuaki","family":"Michihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2023.08.003_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5009\/gnl210167","article-title":"Innovative Target Exploration of NAFLD (ITEN) consortium. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","volume":"16","author":"Moon","year":"2022","journal-title":"Gut Liver"},{"key":"10.1016\/j.jacasi.2023.08.003_bib4","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2023.08.003_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2023.08.003_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/heartjnl-2018-312977","article-title":"Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016","volume":"105","author":"Adderley","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.jacasi.2023.08.003_bib7","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/CIRCULATIONAHA.120.052624","article-title":"Association of blood pressure classification using the 2017 American College of Cardiology\/American Heart Association blood pressure guideline with risk of heart failure and atrial fibrillation","volume":"143","author":"Kaneko","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacasi.2023.08.003_bib8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.22.00083","article-title":"Blood pressure classification using the 2017 ACC\/AHA guideline and heart failure in patients with cancer","volume":"41","author":"Kaneko","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.kint.2022.05.031","article-title":"Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors","volume":"102","author":"Suzuki","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacasi.2023.08.003_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5551\/jat.12.301","article-title":"Metabolic syndrome\u2014definition and diagnostic criteria in Japan","volume":"12","author":"Matsuzawa","year":"2005","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jacasi.2023.08.003_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.amjcard.2021.07.049","article-title":"Relation of the metabolic syndrome to incident colorectal cancer in young adults aged 20 to 49 years","volume":"158","author":"Jimba","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.05.015","article-title":"Association of body weight gain with subsequent cardiovascular event in non-obese general population without overt cardiovascular disease","volume":"308","author":"Kaneko","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2023.08.003_bib13","article-title":"Association of isolated diastolic hypertension based on the cutoff value in the 2017 American College of Cardiology\/American Heart Association blood pressure guidelines with subsequent cardiovascular events in the general population","volume":"9","author":"Kaneko","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.jacasi.2023.08.003_bib14","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib15","first-page":"404","article-title":"Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis","volume":"34","author":"Cholongitas","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib16","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacasi.2023.08.003_bib17","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","article-title":"Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jacasi.2023.08.003_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease","volume":"33","author":"Moon","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jacasi.2023.08.003_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacasi.2023.08.003_bib21","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacasi.2023.08.003_bib22","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1016\/j.numecd.2021.08.049","article-title":"Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study","volume":"31","author":"Morieri","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacasi.2023.08.003_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13519","article-title":"Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: from epidemiology to drug approaches","volume":"51","author":"Dongiovanni","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"24","key":"10.1016\/j.jacasi.2023.08.003_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144079","article-title":"Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans","volume":"5","author":"Boren","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacasi.2023.08.003_bib25","first-page":"476","article-title":"Validity of diagnoses, procedures, and laboratory data in Japanese administrative data","volume":"27","author":"Yamana","year":"2017","journal-title":"J\u00a0Epidemiol"},{"key":"10.1016\/j.jacasi.2023.08.003_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/pds.5213","article-title":"Accuracy of Japanese claims data in identifying diabetes-related complications","volume":"30","author":"Fujihara","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374723002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374723002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:59:26Z","timestamp":1757411966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374723002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2772374723002375"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2023.08.003","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk\u00a0of HF and AF","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}